MedTrace Logo

Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer

NCT02572778 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-12-03

No results posted yet for this study

Summary

The investigators want to have a collection of fresh primary or recurrent tumor tissue for establishment of patients-derived xenografts in order to:

generate a biobank of in vivo patient xenografts representing the different subgroups of tumors for head and neck cancer

* perform genetic and transcriptional profiling of the primary, metastatic tumors and xenograft tumors
* evaluate the efficacy of new targeted agents, whether or not in combination with standard treatment options
* evaluate biomarkers of drug sensitivity
* study primary and secondary (acquired) resistance in these models

Conditions

  • Squamous Cell Carcinoma of the Head and Neck

Interventions

PROCEDURE

Local biopsy in the tumor

A tumor biopsy of 0.5 cm2 or more will be collected from every patient during surgery or endoscopy after informed consent and if there is enough material after review by the pathologist.

Sponsors & Collaborators

  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    lead OTHER

Principal Investigators

  • Jean-Pascal Machiels, MD, PhD · Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02572778 on ClinicalTrials.gov